SCHEDULE: Beryl Capital Exits Enzo Biochem Stake

Sentiment:

Beneficial Ownership Amendment 14 November 2025 2:27 PM

Beryl Capital Management and its affiliates have reported a 0% beneficial ownership in Enzo Biochem Inc., indicating a full divestment or reduction below reporting thresholds.

Worse than expectedBeryl Capital Management and its affiliates have reduced their beneficial ownership in Enzo Biochem Inc. to 0%, indicating a complete exit from their position or a reduction below the 5% reporting threshold, which is generally a negative signal for the stock.

Summary

Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin have filed an Amendment No. 1 to Schedule 13G for Enzo Biochem Inc.
The reporting group now holds 0.00 shares, representing 0% of Enzo Biochem Inc.'s Common Stock.
This indicates a complete divestment of their previously held stake or a reduction below the 5% reporting threshold.
The event requiring this statement occurred on September 30, 2025.

Sentiment

Score: 3

Explanation: The complete divestment by an institutional investor is generally a negative signal for the issuer, suggesting a lack of confidence or a strategic shift away from the company. However, the filing itself is a routine compliance update and doesn't provide explicit reasons for the divestment.

Positives

Negatives

Beryl Capital Management and its affiliates have completely divested their beneficial ownership in Enzo Biochem Inc., reducing their stake to 0%.

Risks

Future Outlook

Management Comments

Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein.

Industry Context

This filing reflects a change in institutional investor sentiment or portfolio strategy regarding Enzo Biochem Inc., a common occurrence in the dynamic biotech and healthcare investment landscape.

Stakeholder Impact

Shareholders may view the complete divestment by Beryl Capital Management as a negative signal, potentially impacting investor confidence and the company's stock price.

Key Dates

Date	Description
09/30/2025	Date of event requiring the filing of this statement (reduction of beneficial ownership below reporting threshold).
11/14/2025	Signature date of the Schedule 13G Amendment No. 1.

Recommendation

sell

The complete divestment of shares by Beryl Capital Management and its affiliates, reducing their beneficial ownership to 0%, signals a lack of confidence or a strategic exit from Enzo Biochem Inc. by a sophisticated institutional investor. While the reasons for the divestment are not disclosed, such a move by a significant holder often precedes or accompanies negative performance or a reassessment of the company's prospects, warranting a 'sell' recommendation for investors to consider reducing their exposure.

Keywords

Enzo Biochem Inc., ENZ, Beryl Capital Management, Schedule 13G, beneficial ownership, divestment, institutional ownership, SEC filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.